With regard to CRS-2 etiological background, patients with nonatherosclerotic compared to patients with atherosclerotic CVD displayed increased counts of intermediate CD14++CD16+ monocytes [75 (IQR, 41–104)/μL versus 36 (IQR, 22–61)/μL (p = 0.01)] and nonclassical CD14+CD16++ monocytes [37 (IQR, 35–49)/μL versus 21 (IQR, 12–32)/μL (p = 0.02)]. This evidence concerns the gene CD14 and craniosynostosis 2.